Page last updated: 2024-08-25

bendamustine hydrochloride and xl765

bendamustine hydrochloride has been researched along with xl765 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awan, FT; Costa, LJ; Gao, L; Gore, L; Lager, J; Sharma, J	1

Trials

1 trial(s) available for bendamustine hydrochloride and xl765

Article	Year
Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. British journal of haematology, 2016, Volume: 175, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Recurrence; Retreatment; Rituximab; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome	2016

Article

Year

Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.

British journal of haematology, 2016, Volume: 175, Issue:1

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Recurrence; Retreatment; Rituximab; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome

2016